A PYMNTS Company

The EC Sector Inquiry Into Pharmaceuticals: Quo Vadis, Commission?

BY | February 25, 2009

This article is part of a Chronicle. See more from this Chronicle Luc Gyselen, Feb 26, 2009 This article will focus on the Commission’s antitrust enforcement agenda and examine two…

This article is part of a Chronicle. See more from this Chronicle

Luc Gyselen, Feb 26, 2009

This article will focus on the Commission’s antitrust enforcement agenda and examine two questions. First, why does the Report in spite of repeated disclaimers that it does not contain any finding of wrongdoing create the impression that the pharmaceutical companies engage in many practices that are unlawful (infra Section 1)? Second, which antitrust policy principles should guide the Commission in

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.215.186.30

Please verify email or join us to access premium content!